125 related articles for article (PubMed ID: 6653642)
1. Chronic propranolol administration during pregnancy. Maternal pharmacokinetics.
Smith MT; Livingstone I; Eadie MJ; Hooper WD; Triggs EJ
Eur J Clin Pharmacol; 1983; 25(4):481-90. PubMed ID: 6653642
[TBL] [Abstract][Full Text] [Related]
2. Propranolol in pregnancy three year prospective study.
Livingstone I; Craswell PW; Bevan EB; Smith MT; Eadie MJ
Clin Exp Hypertens B; 1983; 2(2):341-50. PubMed ID: 6872291
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of propranolol in the human maternal-placental-foetal unit.
Smith MT; Livingstone I; Eadie MJ; Hooper WD; Triggs EJ
Eur J Clin Pharmacol; 1983; 24(6):727-32. PubMed ID: 6884410
[TBL] [Abstract][Full Text] [Related]
4. The influence of pregnancy on drug action: concentration-effect modelling with propranolol.
Rubin PC; Butters L; McCabe R; Kelman A
Clin Sci (Lond); 1987 Jul; 73(1):47-52. PubMed ID: 3608376
[TBL] [Abstract][Full Text] [Related]
5. Effect of dose and uremia on plasma and urine profiles of propranolol metabolites.
Schneck DW; Pritchard JF; Gibson TP; Vary JE; Hayes AH
Clin Pharmacol Ther; 1980 Jun; 27(6):744-55. PubMed ID: 7379441
[TBL] [Abstract][Full Text] [Related]
6. Propranolol, propranolol glucuronide, and naphthoxylactic acid in breast milk and plasma.
Smith MT; Livingstone I; Hooper WD; Eadie MJ; Triggs EJ
Ther Drug Monit; 1983; 5(1):87-93. PubMed ID: 6845404
[TBL] [Abstract][Full Text] [Related]
7. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
[TBL] [Abstract][Full Text] [Related]
8. Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
Ring JA; Ghabrial H; Ching MS; Shulkes A; Smallwood RA; Morgan DJ
Drug Metab Dispos; 1995 Feb; 23(2):190-6. PubMed ID: 7736910
[TBL] [Abstract][Full Text] [Related]
9. The influence of diltiazem versus cimetidine on propranolol metabolism.
Tateishi T; Ohashi K; Fujimura A; Ebihara A
J Clin Pharmacol; 1992 Dec; 32(12):1099-104. PubMed ID: 1487547
[TBL] [Abstract][Full Text] [Related]
10. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol.
Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
Clin Pharmacol Ther; 1980 Jan; 27(1):22-31. PubMed ID: 7351114
[TBL] [Abstract][Full Text] [Related]
11. N-dealkylation of propranolol in rat, dog, and man. Chemical and stereochemical aspects.
Nelson WL; Bartels MJ
Drug Metab Dispos; 1984; 12(3):345-52. PubMed ID: 6145562
[TBL] [Abstract][Full Text] [Related]
12. Product inhibition and dose-dependent bioavailability of propranolol in the isolated perfused rat liver preparation.
Ghabrial H; Nand R; Stead CK; Smallwood RA; Morgan DJ
J Pharm Sci; 1994 Jul; 83(7):931-6. PubMed ID: 7965671
[TBL] [Abstract][Full Text] [Related]
13. Plasma concentrations of propranolol and 4-hydroxypropranolol during chronic oral propranolol therapy.
Wong L; Nation RL; Chiou WL; Mehta PK
Br J Clin Pharmacol; 1979 Aug; 8(2):163-7. PubMed ID: 486291
[TBL] [Abstract][Full Text] [Related]
14. Kinetic and clinical observations in cyanotic children on propranolol therapy.
Riopel DA; Walle T
Clin Pharmacol Ther; 1980 Dec; 28(6):743-50. PubMed ID: 7438690
[TBL] [Abstract][Full Text] [Related]
15. Influence of aging on the oxidative and conjugative metabolism of propranolol.
Tateishi T; Fujimura A; Shiga T; Ohashi K; Ebihara A
Int J Clin Pharmacol Res; 1995; 15(3):95-101. PubMed ID: 8847155
[TBL] [Abstract][Full Text] [Related]
16. The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension.
Serlin MJ; Orme ML; MacIver M; Green GJ; Sibeon RG; Breckenridge AM
Br J Clin Pharmacol; 1983 May; 15(5):519-27. PubMed ID: 6860527
[TBL] [Abstract][Full Text] [Related]
17. Measurement of naphthoxylactic and naphtoxyacetic acid in human plasma following propranolol administration.
Pritchard F; Schneck D; Hayes A
Res Commun Chem Pathol Pharmacol; 1979 Feb; 23(2):279-86. PubMed ID: 461953
[TBL] [Abstract][Full Text] [Related]
18. Massive propranolol metabolite retention during maintenance hemodialysis.
Stone WJ; Walle T
Clin Pharmacol Ther; 1980 Oct; 28(4):449-55. PubMed ID: 7408404
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol.
Rowland K; Yeo WW; Ellis SW; Chadwick IG; Haq I; Lennard MS; Jackson PR; Ramsay LE; Tucker GT
Br J Clin Pharmacol; 1994 Jul; 38(1):9-14. PubMed ID: 7946944
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and identification of 3-(4-hydroxy-1-naphthoxy)lactic acid as a metabolite of propranolol in the rat, in man, and in the rat liver 9000 g supernatant fraction.
Talaat RE; Nelson WL
Drug Metab Dispos; 1986; 14(2):202-7. PubMed ID: 2870895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
